Jounce Therapeutics Stock Price, News & Analysis (NASDAQ:JNCE)

$24.05 -0.18 (-0.74 %)
(As of 02/20/2018 08:24 AM ET)
Previous Close$24.23
Today's Range$24.01 - $24.85
52-Week Range$11.05 - $29.29
Volume144,400 shs
Average Volume321,700 shs
Market Capitalization$775.51 million
P/E Ratio-114.52
Dividend YieldN/A
BetaN/A

About Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics logoJounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Debt-to-Equity RatioN/A
Current Ratio4.13%
Quick Ratio4.13%

Price-To-Earnings

Trailing P/E Ratio-114.52380952381
Forward P/E Ratio-27.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$37.20 million
Price / Sales20.85
Cash FlowN/A
Price / CashN/A
Book Value($2.15) per share
Price / Book-11.19

Profitability

Trailing EPS($0.21)
Net Income$-13,700,000.00
Net Margins-2.03%
Return on Equity-1.39%
Return on Assets-0.50%

Miscellaneous

Employees85
Outstanding Shares32,250,000

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. The company earned $18.10 million during the quarter, compared to analyst estimates of $20 million. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The business's revenue for the quarter was up 7.1% on a year-over-year basis. View Jounce Therapeutics' Earnings History.

Where is Jounce Therapeutics' stock going? Where will Jounce Therapeutics' stock price be in 2018?

4 Wall Street analysts have issued 1 year price targets for Jounce Therapeutics' stock. Their predictions range from $28.00 to $30.00. On average, they expect Jounce Therapeutics' share price to reach $29.00 in the next year. View Analyst Ratings for Jounce Therapeutics.

What are Wall Street analysts saying about Jounce Therapeutics stock?

Here are some recent quotes from research analysts about Jounce Therapeutics stock:

  • 1. According to Zacks Investment Research, "Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. " (1/17/2018)
  • 2. Cowen Inc analysts commented, "Jounce provided an interim update from the ICONIC trial." (6/9/2017)

Who are some of Jounce Therapeutics' key competitors?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:

  • Perry Karsen, Chairman of the Board (Age 62)
  • Richard Murray Ph.D., President, Chief Executive Officer, Director (Age 58)
  • James P. Allison Ph.D., Co-Founder
  • Thomas F. Gajewski M.D. Ph.D., Co-Founder
  • Drew Pardoll M.D. Ph.D., Co-Founder
  • Padmanee Sharma M.D. Ph.D., Co-Founder
  • Kimberlee Cobleigh Drapkin CPA, Chief Financial Officer, Treasurer (Age 49)
  • Deborah Law, Chief Scientific Officer
  • Elizabeth G. Trehu M.D., Chief Medical Officer (Age 56)
  • Luis A. Diaz Jr. M.D., Director

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who owns Jounce Therapeutics stock?

Jounce Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.60%), Redmile Group LLC (3.04%), Brown Advisory Inc. (1.52%), Millennium Management LLC (0.76%), Acadian Asset Management LLC (0.76%) and Spark Investment Management LLC (0.47%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc and John Duncan Higgons. View Institutional Ownership Trends for Jounce Therapeutics.

Who sold Jounce Therapeutics stock? Who is selling Jounce Therapeutics stock?

Jounce Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Goldman Sachs Group Inc., Artal Group S.A., Strs Ohio, TIAA CREF Investment Management LLC, Spark Investment Management LLC and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. View Insider Buying and Selling for Jounce Therapeutics.

Who bought Jounce Therapeutics stock? Who is buying Jounce Therapeutics stock?

Jounce Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, J. Goldman & Co LP, First Manhattan Co., Tocqueville Asset Management L.P., Virtus Fund Advisers LLC, Vident Investment Advisory LLC and Redmile Group LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy Jounce Therapeutics stock?

Shares of Jounce Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of Jounce Therapeutics stock can currently be purchased for approximately $24.05.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $775.51 million and generates $37.20 million in revenue each year. The company earns $-13,700,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Jounce Therapeutics employs 85 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (JNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Jounce Therapeutics (NASDAQ:JNCE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$29.00$29.00
Price Target Upside: 95.81% upside95.81% upside95.81% upside66.19% upside

Jounce Therapeutics (NASDAQ:JNCE) Consensus Price Target History

Price Target History for Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics (NASDAQ:JNCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017JPMorgan Chase & Co.Set Price TargetBuy$28.00N/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingBuy$30.00N/AView Rating Details
6/9/2017CowenReiterated RatingBuyLowView Rating Details
2/21/2017Wells Fargo & CoInitiated CoverageOutperform -> OutperformN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Jounce Therapeutics (NASDAQ:JNCE) Earnings History and Estimates Chart

Earnings by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics (NASDAQ JNCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.25)($0.13)$20.00 million$18.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.15)($0.11)$19.94 million$20.29 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.09)($0.02)$19.71 million$20.30 millionViewN/AView Earnings Details
3/10/201712/31/2016$0.04$0.05$15.00 million$20.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Jounce Therapeutics (NASDAQ:JNCE) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS

Dividends

Dividend History for Jounce Therapeutics (NASDAQ:JNCE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Jounce Therapeutics (NASDAQ JNCE) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 87.81%
Insider Trades by Quarter for Jounce Therapeutics (NASDAQ:JNCE)
Insider Trades by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics (NASDAQ JNCE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/26/2018Barbara Gayle DuncanDirectorSell4,000$25.00$100,000.004,000View SEC Filing  
2/1/2017Celgene Switzerland LlcMajor ShareholderBuy625,000$16.00$10,000,000.00View SEC Filing  
2/1/2017John Duncan HiggonsDirectorBuy6,700$16.00$107,200.0027,025View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Jounce Therapeutics (NASDAQ JNCE) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Quarterly Sales of $15.64 MillionZacks: Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Quarterly Sales of $15.64 Million
www.americanbankingnews.com - February 18 at 6:02 AM
Jounce Therapeutics (JNCE) versus Its Competitors Financial ReviewJounce Therapeutics (JNCE) versus Its Competitors Financial Review
www.americanbankingnews.com - February 17 at 7:32 PM
Zacks: Brokerages Expect Jounce Therapeutics Inc (JNCE) Will Post Earnings of -$0.59 Per ShareZacks: Brokerages Expect Jounce Therapeutics Inc (JNCE) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - February 16 at 7:58 AM
3 Boom-or-Bust Biotech Stocks to Buy in 20183 Boom-or-Bust Biotech Stocks to Buy in 2018
finance.yahoo.com - February 12 at 6:37 AM
 Jounce Therapeutics Inc (JNCE) Given $29.00 Consensus Price Target by Brokerages Jounce Therapeutics Inc (JNCE) Given $29.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - February 12 at 3:34 AM
Financial Survey: MacroGenics (MGNX) & Jounce Therapeutics (JNCE)Financial Survey: MacroGenics (MGNX) & Jounce Therapeutics (JNCE)
www.americanbankingnews.com - February 8 at 5:14 PM
Zacks: Analysts Set $29.00 Price Target for Jounce Therapeutics Inc (JNCE)Zacks: Analysts Set $29.00 Price Target for Jounce Therapeutics Inc (JNCE)
www.americanbankingnews.com - February 6 at 10:40 AM
Zacks: Jounce Therapeutics Inc (JNCE) Given Average Rating of "Strong Buy" by BrokeragesZacks: Jounce Therapeutics Inc (JNCE) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 2 at 7:22 PM
Zacks: Brokerages Expect Jounce Therapeutics Inc (JNCE) Will Announce Quarterly Sales of $15.64 MillionZacks: Brokerages Expect Jounce Therapeutics Inc (JNCE) Will Announce Quarterly Sales of $15.64 Million
www.americanbankingnews.com - February 1 at 6:14 AM
 Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Earnings of -$0.59 Per Share Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - January 30 at 9:23 AM
Barbara Gayle Duncan Sells 4,000 Shares of Jounce Therapeutics Inc (JNCE) StockBarbara Gayle Duncan Sells 4,000 Shares of Jounce Therapeutics Inc (JNCE) Stock
www.americanbankingnews.com - January 29 at 9:12 PM
Financial Analysis: Jounce Therapeutics (JNCE) versus Its PeersFinancial Analysis: Jounce Therapeutics (JNCE) versus Its Peers
www.americanbankingnews.com - January 26 at 5:04 PM
Jounce Therapeutics, Inc. (Nasdaq: JNCE) to Ring the Nasdaq Stock Market Closing BellJounce Therapeutics, Inc. (Nasdaq: JNCE) to Ring the Nasdaq Stock Market Closing Bell
finance.yahoo.com - January 26 at 3:25 PM
Head to Head Comparison: Jounce Therapeutics (JNCE) versus Its PeersHead to Head Comparison: Jounce Therapeutics (JNCE) versus Its Peers
www.americanbankingnews.com - January 25 at 9:02 PM
Contrasting Jounce Therapeutics (JNCE) & Its CompetitorsContrasting Jounce Therapeutics (JNCE) & Its Competitors
www.americanbankingnews.com - January 23 at 9:28 AM
 Jounce Therapeutics Inc (JNCE) Given Average Rating of "Strong Buy" by Analysts Jounce Therapeutics Inc (JNCE) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - January 17 at 5:14 AM
 Brokerages Set $29.00 Price Target for Jounce Therapeutics Inc (JNCE) Brokerages Set $29.00 Price Target for Jounce Therapeutics Inc (JNCE)
www.americanbankingnews.com - January 13 at 1:58 PM
 Brokerages Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Earnings of -$0.59 Per Share Brokerages Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - January 13 at 11:26 AM
Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-17 1:00pm GMTEdited Transcript of JNCE.O earnings conference call or presentation 13-Nov-17 1:00pm GMT
finance.yahoo.com - January 12 at 4:11 PM
Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceJounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:53 AM
Jounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $15.64 MillionJounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $15.64 Million
www.americanbankingnews.com - December 29 at 8:32 AM
 Jounce Therapeutics Inc (JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages Jounce Therapeutics Inc (JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 28 at 1:10 AM
 Analysts Expect Jounce Therapeutics Inc (JNCE) to Announce -$0.59 EPS Analysts Expect Jounce Therapeutics Inc (JNCE) to Announce -$0.59 EPS
www.americanbankingnews.com - December 27 at 5:36 PM
Jounce Therapeutics Added to NASDAQ Biotechnology IndexJounce Therapeutics Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 14 at 10:50 AM
Brokerages Anticipate Jounce Therapeutics Inc (JNCE) to Post ($0.59) Earnings Per ShareBrokerages Anticipate Jounce Therapeutics Inc (JNCE) to Post ($0.59) Earnings Per Share
www.americanbankingnews.com - December 13 at 7:52 AM
 Analysts Expect Jounce Therapeutics Inc (JNCE) Will Post Quarterly Sales of $15.64 Million Analysts Expect Jounce Therapeutics Inc (JNCE) Will Post Quarterly Sales of $15.64 Million
www.americanbankingnews.com - December 12 at 10:12 AM
 Analysts Anticipate Jounce Therapeutics Inc (JNCE) to Post -$0.59 Earnings Per Share Analysts Anticipate Jounce Therapeutics Inc (JNCE) to Post -$0.59 Earnings Per Share
www.americanbankingnews.com - December 10 at 7:28 AM
Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceJounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 11:05 AM
Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : December 5, 2017Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : December 5, 2017
finance.yahoo.com - December 5 at 12:24 PM
Brokerages Expect Jounce Therapeutics, Inc. (JNCE) to Post ($0.49) EPSBrokerages Expect Jounce Therapeutics, Inc. (JNCE) to Post ($0.49) EPS
www.americanbankingnews.com - November 26 at 9:34 AM
Jounce Therapeutics, Inc. (JNCE) PT Set at $28.00 by J P Morgan Chase & CoJounce Therapeutics, Inc. (JNCE) PT Set at $28.00 by J P Morgan Chase & Co
www.americanbankingnews.com - November 25 at 6:10 PM
Critical Survey: Dynavax Technologies (DVAX) and Jounce Therapeutics (JNCE)Critical Survey: Dynavax Technologies (DVAX) and Jounce Therapeutics (JNCE)
www.americanbankingnews.com - November 25 at 3:20 PM
Jounce Therapeutics, Inc. (JNCE) Upgraded to Hold by Zacks Investment ResearchJounce Therapeutics, Inc. (JNCE) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - November 25 at 9:08 AM
Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : November 24, 2017Jounce Therapeutics, Inc. – Value Analysis (NASDAQ:JNCE) : November 24, 2017
finance.yahoo.com - November 24 at 5:03 PM
Jounce Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JNCE-US : November 23, 2017Jounce Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JNCE-US : November 23, 2017
finance.yahoo.com - November 23 at 5:00 PM
Jounce Therapeutics, Inc. (JNCE) Expected to Post Earnings of -$0.49 Per ShareJounce Therapeutics, Inc. (JNCE) Expected to Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - November 22 at 9:40 AM
Can This Tiny Biotech Stock Pay Off Big for Celgene?Can This Tiny Biotech Stock Pay Off Big for Celgene?
finance.yahoo.com - November 17 at 9:17 AM
Jounce Therapeutics, Inc. (JNCE) Posts Quarterly  Earnings Results, Beats Expectations By $0.12 EPSJounce Therapeutics, Inc. (JNCE) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - November 14 at 11:24 AM
Jounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call TranscriptJounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call Transcript
www.fool.com - November 13 at 12:58 PM
Jounce Therapeutics Reports Third Quarter 2017 Financial ResultsJounce Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 13 at 9:44 AM
Zacks: Jounce Therapeutics, Inc. (JNCE) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Jounce Therapeutics, Inc. (JNCE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 11 at 3:28 PM
Jounce Therapeutics to Present at the Stifel 2017 Healthcare ConferenceJounce Therapeutics to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 11 at 2:44 PM
Jounce Therapeutics, Inc. (JNCE) Receives Buy Rating from Robert W. BairdJounce Therapeutics, Inc. (JNCE) Receives Buy Rating from Robert W. Baird
www.americanbankingnews.com - November 11 at 12:10 PM
Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingJounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - November 8 at 11:07 AM
Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
finance.yahoo.com - November 8 at 11:07 AM
Jounce Therapeutics, Inc. (JNCE) Expected to Post Quarterly Sales of $20.00 MillionJounce Therapeutics, Inc. (JNCE) Expected to Post Quarterly Sales of $20.00 Million
www.americanbankingnews.com - November 4 at 8:22 AM
-$0.25 EPS Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter-$0.25 EPS Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter
www.americanbankingnews.com - November 2 at 3:18 PM
Jounce Therapeutics Is Now Oversold (JNCE)Jounce Therapeutics Is Now Oversold (JNCE)
www.thestreet.com - October 26 at 3:17 PM
Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of DirectorsJounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
finance.yahoo.com - October 23 at 7:48 PM
Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017
finance.yahoo.com - October 20 at 1:43 AM

SEC Filings

Jounce Therapeutics (NASDAQ:JNCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Jounce Therapeutics (NASDAQ:JNCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Jounce Therapeutics (NASDAQ JNCE) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.